Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate
on the intrahepatic biodistribution in patients with NET liver metastases. Our primary
objective is to evaluate if there is a difference in post-treatment tumor-to-non-tumor (T/N)
activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and
the intravenous treated liver lobe.